Disrupted-in-Schizophrenia-1 (DISC1) is a risk factor for major mental illness, including schizophrenia and depression.
1 DISC1 interacts with multiple proteins involved in intracellular signalling pathways, including two enzymes cAMP phosphodiesterase-4 (PDE4) 2 and glycogen synthase kinase-3b (GSK3b), 3 that are inhibited by the prototypic antidepressant/antipsychotic Rolipram 4 and the mood stabiliser Lithium (LiCl), 5 respectively. PDE4 itself has been directly implicated as a risk factor for mental illness, 1, 2, 6 whereas the likely involvement of GSK3b in molecular pathways underlying mental illness is long standing and now linked to DISC1.
7 DISC1 inhibits GSK3b, 3 and we have previously suggested that DISC1 similarly modulates PDE4. 2 These enzymes have overlapping binding sites on DISC1, 3, 8 suggesting that their function within the DISC1 complex may be related. Moreover, it has recently been demonstrated that GSK3b phosphorylates PDE4D. 9 Accordingly, we now provide evidence that pharmacological inhibition of GSK3b decreases PDE4 activity, and demonstrate that the stimulatory effect of Forskolin upon PDE4 activity is modulated by the co-ordinated action of DISC1 and GSK3b.
Treatment of the human neuroblastoma cell line SH-SY5Y with 10 mM LiCl, a non-selective inhibitor of GSK3b, results in increased cAMP accumulation (Figure 1a , P = 0.000006), suggesting that GSK3b modulates cellular cAMP levels. We therefore performed phosphodiesterase activity assays on SH-SY5Y cells to determine if LiCl effects on cAMP levels involved PDE4. At basal cAMP levels, a trend towards PDE4 inhibition was observed after treatment with 3 mM LiCl, and significantly decreased PDE4 activity was observed at 10 mM LiCl ( Figure 1b , P = 0.000001), suggesting that GSK3b has a tonic-activating effect on PDE4. A decrease in PDE4 activity was also observed after treatment with 3 mM SB216763, a GSK3b-specific inhibitor (Figure 1b , P = 0.007). There was no detectable additive effect of treatment with LiCl and SB216763, (Figure 1b) , suggesting that both compounds modulate PDE4 through the same mechanism, inhibition of GSK3b.
To assess the potential effects of DISC1 overexpression on PDE4 activity, a stably transfected SH-SY5Y cell line was created, which inducibly overexpresses full-length wild-type human DISC1 (fl-DISC, Supplementary Figure S1a ). At basal cAMP levels, DISC1 overexpression does not, by itself, influence PDE4 activity (Bradshaw et al., in preparation), but it does increase the magnitude of the PDE4 inhibitory response to LiCl (Figure 1c) . PDE4 activity was reduced by 26.2% ( ± 3.5) in response to 10 mM LiCl in cells overexpressing fl-DISC1, in contrast to the 16% (±1.7) reduction in activity observed in control cells (P = 0.05). Thus, in SH-SH5Y cells, overexpression of fl-DISC1 enhances the effect of pharmacological inhibition of GSK3b.
Earlier studies have demonstrated that long PDE4 isoforms are phosphorylated and activated by protein kinase A when cellular cAMP levels are elevated; thus, a regulatory negative-feedback loop exists whereby cAMP levels are modulated by the integrated actions of PDE4 and PKA. 10 As expected, treatment of wild-type SH-SY5Y cells with 10 mM Forskolin to activate adenylyl cyclase and increase intracellular cAMP significantly increases PDE4 activity ( Figure  1d , P = 0.00005). This increase is apparently blocked by LiCl treatment. However, when the reduced basal PDE4 activity in LiCl-treated cells (Figure 1b , lower dashed line in Figure 1d ) is taken into account, it is apparent that induction does indeed occur in response to Forskolin, albeit to a lesser extent. Overexpression of DISC1 alone also suppresses induction of PDE4 activity (Figure 1d , P = 0.02, Bradshaw et al., in preparation) in response to Forskolin, an effect that is enhanced by LiCl treatment (Figure 1d , P = 0.01). However, there is no significant difference between the effect of LiCl alone and DISC1 plus LiCl on the induction of PDE4 activity in response to Forskolin. Taken together, these data suggest that the inhibition of PDE4 activity by LiCl limits subsequent PDE4 activity induction, and in turn, any effect of DISC1 overexpression upon induction.
In summary, our data suggest that GSK3b activity is required to maintain a tonic activation of PDE4-dependent cAMP hydrolysis activity in SH-SY5Y cells, whereas DISC1 predominantly modulates PDE4 responses to changing cellular cAMP levels. DISC1, GSK3b and PDE4 have each been identified as risk factors for major mental illness by genetic and/or functional studies. This study points to an integrated, dynamic and co-ordinated effect of all three proteins on cellular cAMP, implicating aberrant cAMP signalling as a mediator of risk for psychiatric illness and as a primary therapeutic target, through genetic and/or pharmacological manipulation.
